{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:01:18Z","timestamp":1771801278561,"version":"3.50.1"},"reference-count":21,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: A total of 50% of patients with AL amyloidosis have t(11;14) translocation, allowing us to use the selective oral BCL-2 inhibitor venetoclax in their treatment. Case presentation: Our patient was admitted to the gastroenterology department due to weight loss and abdominal pain. An abdominal CT scan revealed some enlarged lymph nodes; therefore, he was referred to the hematology department. A bone marrow biopsy showed massive amorphous amyloid deposition. The sample was positive on Congo red staining and exhibited double refraction under a polarized light microscope. Serum-free light chains and the difference between involved and uninvolved free light chains (dFLCs) were elevated. Using fluorescent in situ hybridization, we detected t(11;14) translocation. Further examinations confirmed the involvement of the liver, colon and heart. Stage II AL amyloidosis was confirmed. Our patient received combined induction therapy with CyBorD and venetoclax due to the presence of the t(11;14) translocation. After six cycles, the patient achieved complete remission. Autologous stem cell transplantation (ASCT) was performed. At 100 days post-ASCT, the patient had complete hematologic remission. Venetoclax maintenance treatment was initiated. The follow-up examinations showed that the patient is in very good partial remission. Conclusions: In the case of our AL amyloidosis patient with t(11;14) translocation, the combined treatment with CyBorD and venetoclax was well tolerated and effective.<\/jats:p>","DOI":"10.3390\/curroncol32020063","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T11:38:49Z","timestamp":1737977929000},"page":"63","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation"],"prefix":"10.3390","volume":"32","author":[{"given":"Gr\u00e9ta","family":"Garami","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Obajed Al-Ali","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Virga","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Guly\u00e1s","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9617-0156","authenticated-orcid":false,"given":"Judit","family":"Bedekovics","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-101X","authenticated-orcid":false,"given":"Istv\u00e1n","family":"Tornai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-8668","authenticated-orcid":false,"given":"Ferenc","family":"Magyari","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1556\/OH.2012.29336","article-title":"AL-amyloidosis","volume":"153","year":"2012","journal-title":"Orvosi Hetil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2015.62.4015","article-title":"Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study","volume":"33","author":"Dispenzieri","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","first-page":"593460","article-title":"AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report","volume":"2012","author":"Bowen","year":"2012","journal-title":"Case Rep. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-023-00945-0","article-title":"Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: Benchmark for new therapies","volume":"13","author":"Bal","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.3324\/haematol.2017.183749","article-title":"Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone","volume":"103","author":"Leung","year":"2018","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728214.2020.1803829","article-title":"Emerging drugs for the treatment of light chain amyloidosis","volume":"25","author":"Chakraborty","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000507724","article-title":"Nonchemotherapy treatment of immunoglobulin light chain amyloidosis","volume":"143","author":"Lentzsch","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.clml.2019.07.003","article-title":"Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?","volume":"19","author":"Premkumar","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","article-title":"Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers","volume":"28","author":"Szita","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_14","first-page":"2392","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.19042","article-title":"Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy","volume":"203","author":"Theodorakakou","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lebel, E., Kastritis, E., Palladini, G., Milani, P., Theodorakakou, F., Aumann, S., Lavi, N., Shargian, L., Magen, H., and Cohen, Y. (2023). Venetoclax in Relapse\/Refractory AL Amyloidosis\u2014A Multicenter International Retrospective Real-World Study. Cancers, 15.","DOI":"10.3390\/cancers15061710"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.18632\/oncotarget.28415","article-title":"Systemic AL amyloidosis: Current approach and future direction","volume":"14","author":"Zerdan","year":"2023","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ajh.25572","article-title":"Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis","volume":"94","author":"Sidiqi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2298\/VSP0906482F","article-title":"Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis","volume":"66","author":"Faust","year":"2009","journal-title":"Vojnosanit. Pregl."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:19Z","timestamp":1759919779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020063"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020063","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}